A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of β‑thalassemia major: A case report

  • Palomo‑Colli M
  • Zapata‑Tarres M
  • Castel�n‑Mart�nez O
  • et al.
N/ACitations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Acute lymphoblastic leukemia (ALL) has been suggested as a long-term complication in patients with β-thalassemia major (β-TM). A 12-months-old male patient was diagnosed with β-TM. The patient required a blood transfusion weekly for 2 years. At the age of 4 years, a splenectomy was performed due to massive splenomegaly and frequent transfusion requirements. The histopathological analysis of the spleen revealed extensive hemosiderosis. ALL-L1 with the T immunophenotype and without central nervous system (CNS) involvement was diagnosed when the patient was 5 years old, and treated with anti-leukemic combination chemotherapy and CNS radiotherapy. The patient completed 24 months of treatment and has been in complete remission for 7 years, without long-term adverse events.

Cite

CITATION STYLE

APA

Palomo‑Colli, M., Zapata‑Tarres, M., Castel�n‑Mart�nez, O., Ju�rez‑Villegas, L., & C�rdova‑Hurtado, L. (2017). A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of β‑thalassemia major: A case report. Molecular and Clinical Oncology. https://doi.org/10.3892/mco.2017.1533

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free